Dr. Pastan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
national cancer institute
37 convent lane
Bethesda, MD 20892Phone+1 240-760-6470
Education & Training
Tufts University School of MedicineClass of 1957
Awards, Honors, & Recognition
- Elected Member Institute of Medicine, 2010
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors Start of enrollment: 1998 May 01
Publications & Presentations
PubMed
- 39 citationsLoss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor.Sebastian Stahl, Ana Rita Da Silva Mateus Seidl, Axel Ducret, Sabine Kux van Geijtenbeek, Sven Michel
Proceedings of the National Academy of Sciences of the United States of America. 2015-08-25 - 421 citationsAnti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemiaWaleed Haso, Daniel W. Lee, Nirali N. Shah, Maryalice Stetler-Stevenson, Constance M. Yuan
Blood. 2013-02-14 - 162 citationsMoxetumomab pasudotox in relapsed/refractory hairy cell leukemia.Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Lionel Karlin
Leukemia. 2018-07-20
Abstracts/Posters
- Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 TrialIra Pastan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Biologic Therapeutics Seminar Series - Systems Approaches to Antibody-based Immunotherapy of CancerWashington University School of Medicine, Saint Louis, Missouri - 5/16/2012
Press Mentions
NCI Opens New Immunotherapy Clinical Trial for MesotheliomaJanuary 4th, 2022- NCI Studying New Mesothelioma Immunotherapy CombinationJuly 8th, 2020
US FDA Approves LUMOXITI™ (Moxetumomab Pasudotox-Tdfk) for Certain Patients with Relapsed or Refractory Hairy Cell LeukemiaSeptember 13th, 2018
Grant Support
- Growth Regulation SectionNational Cancer Institute2008
- Immunotoxin Therapy Of Solid And Hematopoietic Tumors: Preclinical StudiesNational Cancer Institute2007–2008
- Gene DiscoveryNational Cancer Institute2007
- Immunotoxin Therapy Of Solid And Hematopoietic Tumors: PDivision Of Basic Sciences - Nci2002–2006
- Gene DiscoveryDivision Of Basic Sciences - Nci1998–2006
- Immunotoxin Therapy Of Solid And Hematopoietic TumorsDivision Of Basic Sciences - Nci2003–2004
- Immunotoxin Therapy In CancerDivision Of Basic Sciences - Nci2001
- Immunotoxin Therapy Of Solid And Hematopoietic Tumors: Preclinical StudiesDivision Of Basic Sciences - Nci2000
- Immunotoxin Therapy Of Solid And Hematopoietic Tumors: Preclinical StudiesDivision Of Basic Sciences - Nci1999
- Immunotoxin Therapy Of OLID Tumors--Preclinical StudiesDivision Of Basic Sciences - Nci1997–1998
- Immunotoxins And Recombinant Toxin Therapy Of CancerDivision Of Basic Sciences - Nci1996
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
